Biolingus

a breakthrough platform technology for stabilising & oral drug delivery of peptides, cytokines, anti TNF alpha & vaccines

[Biolingus @Biolingus]

Biz #partnership is all about valuing core competence of each other& derive exponential Gr% prospects in association https://t.co/eOatoANZ2Z

[Biolingus @Biolingus]

@tedhameda https://t.co/coovmS2vKn

[Biolingus @Biolingus]

Creating holobiont of partnerships taking to flux of creating value thru skill platform to flexible knowledge sharing,both product/geography

[Biolingus @Biolingus]

Non-invasive delivery of biological drugs:holy grail in pharmaceutical industry? https://t.co/TCKcGQaPeh via @Business Worldwide Magazine

[European CEO @europeanceo]

Technological innovation can advance the non-invasive delivery of biological drugs , says @Biolingus

https://t.co/3ek9XNYF91

[Biolingus @Biolingus]

Common to #NDDS tech; well ahead of times, when developed, real exciting commercial output realised; when relevant #therapy peaks #Biolingus

[Biolingus @Biolingus]

Must listen..... @melindarichter https://t.co/a6SVk9mi4d

[Atul Sharma @sharma6669]

Melinda Richter, Head of JLABS https://t.co/h9Q5UduGEQ via @YouTube

[Atul Sharma @sharma6669]

2015 In Review: Initial public offerings – FirstWord Pharma https://t.co/IWIvtGFqo9

[FirstWord Pharma @fwpharma]

2015 In Review: #Pharma's largest in-licensing deals – cancer continues to carry the day https://t.co/iKGjxH0r12

[Biolingus @Biolingus]

Wish all a very happy & prosperous new year...let #Biolingus be trusted partner for deliverance of better healthcare to all - 2016

[Atul Sharma @sharma6669]

Knowledge pooling leading to mutual commercial success https://t.co/ur5zNde69g

[Biolingus @Biolingus]

Scaling up of #Biotech R&D is tangentially different ball game getting from an orbit to another #Biolingus

[Atul Sharma @sharma6669]

Business #partnership is all about acknowledging strength of partner #pharma #biotech either is geography entrenchment or IP

[Atul Sharma @sharma6669]

Biobetters in therapies introduced post patent expiry;may eventually take share from d other products in class besides expanding market size

[Atul Sharma @sharma6669]

Biz turnaround can become integral part as SBU for some sectors-which turns around&spinning off revived biz&ensures definite revenue stream

[Atul Sharma @sharma6669]

Biz #partnership is all about acknowledging & valuing core competence of each other & derive exponential #growth prospects in association

[Pharmaceutical Market Europe @PMLiVEcom]

GSK plans sirukumab filing in rheumatoid arthritis next year https://t.co/hfarZPTE9N #pharma

[Josh Berlin @BioPharmaJosh]

.@Frank_S_David no breakdown, but 2014 IMS report says 32% of global NMEs not available in US

[Bio Stocks™ @BioStocks]

$GILD $GLPG Upfront $725M. Consisting of $300M licensing fee + $425M equity investment. Up to $1.35B in milestones + double-digit royalties

[Biolingus @Biolingus]

~2bn getting 10x"@sharma6669: Skeptics who fail to applaud disruption/breakthrough tech - now what will they call https://t.co/eJbHSdF0Hf"

[Atul Sharma @sharma6669]

Thrilling to get in path breaking #therapy w/ #novel #drugdelivery tech being launched #market #pricing #marketshare #competitors #biolingus